American Gastroenterological Association
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management.
The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.
Source and rights
Published by Gastroenterology, 2021. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- American Gastroenterological Association
- Published
- 2021
- Applies to
- 🇺🇸 United States
- Scope
- National
- Journal
- Gastroenterology
- PubMed
- 33080231
More in gastroenterology and hepatology
- Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)European Respiratory Society · 2026
- AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert ReviewAmerican Gastroenterological Association Institute · 2026
